SKLB610

Potent VEGFR inhibitor CAS# 1125780-41-7

SKLB610

Catalog No. BCC3647----Order now to get a substantial discount!

Product Name & Size Price Stock
SKLB610: 5mg $92 In Stock
SKLB610: 10mg Please Inquire In Stock
SKLB610: 20mg Please Inquire Please Inquire
SKLB610: 50mg Please Inquire Please Inquire
SKLB610: 100mg Please Inquire Please Inquire
SKLB610: 200mg Please Inquire Please Inquire
SKLB610: 500mg Please Inquire Please Inquire
SKLB610: 1000mg Please Inquire Please Inquire
Related Products

Quality Control of SKLB610

Number of papers citing our products

Chemical structure

SKLB610

3D structure

Chemical Properties of SKLB610

Cas No. 1125780-41-7 SDF Download SDF
PubChem ID 25230662 Appearance Powder
Formula C21H16F3N3O3 M.Wt 415.4
Type of Compound N/A Storage Desiccate at -20°C
Solubility >20.8mg/mL in DMSO
Chemical Name N-methyl-4-[4-[[3-(trifluoromethyl)benzoyl]amino]phenoxy]pyridine-2-carboxamide
SMILES CNC(=O)C1=NC=CC(=C1)OC2=CC=C(C=C2)NC(=O)C3=CC(=CC=C3)C(F)(F)F
Standard InChIKey WACDHHMEVMSODJ-UHFFFAOYSA-N
Standard InChI InChI=1S/C21H16F3N3O3/c1-25-20(29)18-12-17(9-10-26-18)30-16-7-5-15(6-8-16)27-19(28)13-3-2-4-14(11-13)21(22,23)24/h2-12H,1H3,(H,25,29)(H,27,28)
General tips For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months.
We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months.
Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it.
About Packaging 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial.
2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial.
3. Try to avoid loss or contamination during the experiment.
Shipping Condition Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request.

Biological Activity of SKLB610

DescriptionSKLB610 is a novel multi-targeted inhibitor of angiogenesis-related tyrosine kinase.
TargetsFGFR    

Protocol

Kinase Assay [1]
The inhibitory ability of SKLB610 on kinase activity is determined using labeled γ-P33ATP. Peptide as kinase substrates are monitored by labeled phosphate. Briefly, 10mU human VEGFR2, FGFR2, PDGFR-E EGFR, PI3K, Aurora-A, CDK2/ cyclinE and CDK6/cyclinD3 are incubated with 25μL solution containing SKLB610 or vehicle (8mM MOPS pH 7.0, 0.2mM EDTA, 10mM Mg Acetate, 10μM [γ-P33ATP] and their own peptide as substrate. The reaction is initiated by the addition of the MgATP mix. After incubation for 40 minutes, the reaction is stopped by the addition of 5μL of a 3% phosphoric acid solution. 10 μL of the reaction is then spotted onto a P30 filtermat and washed three times for 5 minutes in 75mM phosphoric acid and once in methanol prior to drying. Finally, kinase activity is detected using scintillation counting method[1].

Cell Assay [1]
The effect of SKLB610 on cell viability is evaluated by CCK-8 assay. Briefly, cell are seeded in 96-well plates (2000-4000 cells/well) for 24h, followed by SKLB610 treatment at concentrations of 1.25-40 μM for 48h. After the culture period, the supernatant fluid is removed and medium contains 10% CCK- 8 reagent is added for 2-4 h incubation at 37°C. The light absorptions (OD) are measured at 450 nm with microplate spectrophotometer[1].

Animal Administration [2]
Rats: Rats are fasted for 12 h with free access to water before administration and divided randomly into two groups. SKLB610 suspension and SKLB610 solution at a dose of 50 mg/kg SKLB610 are administered. A 250-μL blood sample is collected into heparinized tubes by retro-orbital puncture at 0.083, 0.25, 0.5, 1, 2, 3, 4, 8, 10, 12 and 24 h after a single dose by administration of 50 mg/kg SKLB610. The blood samples are centrifuged at 7,000 rpm for 10 min to obtain the plasma. The plasma samples are stored at -20°C until analysis[2].

References:
[1]. Cao ZX, et al. SKLB610: a novel potential inhibitor of vascular endothelial growth factor receptor tyrosine kinases inhibits angiogenesis and tumor growth in vivo. Cell Physiol Biochem. 2011;27(5):565-74. [2]. Luo X, et al. Pharmacokinetic studies of a novel multikinase inhibitor for treating cancer by HPLC-UV. J Chromatogr Sci. 2013 Jan;51(1):17-20.

SKLB610 Dilution Calculator

Concentration (start)
x
Volume (start)
=
Concentration (final)
x
Volume (final)
 
 
 
C1
V1
C2
V2

calculate

SKLB610 Molarity Calculator

Mass
=
Concentration
x
Volume
x
MW*
 
 
 
g/mol

calculate

Preparing Stock Solutions of SKLB610

1 mg 5 mg 10 mg 20 mg 25 mg
1 mM 2.4073 mL 12.0366 mL 24.0732 mL 48.1464 mL 60.183 mL
5 mM 0.4815 mL 2.4073 mL 4.8146 mL 9.6293 mL 12.0366 mL
10 mM 0.2407 mL 1.2037 mL 2.4073 mL 4.8146 mL 6.0183 mL
50 mM 0.0481 mL 0.2407 mL 0.4815 mL 0.9629 mL 1.2037 mL
100 mM 0.0241 mL 0.1204 mL 0.2407 mL 0.4815 mL 0.6018 mL
* Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations.

Organizitions Citing Our Products recently

 
 
 

Calcutta University

University of Minnesota

University of Maryland School of Medicine

University of Illinois at Chicago

The Ohio State University

University of Zurich

Harvard University

Colorado State University

Auburn University

Yale University

Worcester Polytechnic Institute

Washington State University

Stanford University

University of Leipzig

Universidade da Beira Interior

The Institute of Cancer Research

Heidelberg University

University of Amsterdam

University of Auckland
TsingHua University
TsingHua University
The University of Michigan
The University of Michigan
Miami University
Miami University
DRURY University
DRURY University
Jilin University
Jilin University
Fudan University
Fudan University
Wuhan University
Wuhan University
Sun Yat-sen University
Sun Yat-sen University
Universite de Paris
Universite de Paris
Deemed University
Deemed University
Auckland University
Auckland University
The University of Tokyo
The University of Tokyo
Korea University
Korea University

Background on SKLB610

SKLB610 is a selective inhibitor of VEGFR with IC50 value of 2.2 μM [1].

VEGFR (vascular endothelial growth factor receptor) are receptors for VEGF and plays an important role in stimulating cellular response by cooperating with VEGF. It has been reported that VEGFR abnormally expressed in a variety of cancers and its inhibitors has been regarded as a promising strategy in clinic [1, 2].

SKLB610 is a potent VEGF induced VEGF2 phosphorylation inhibitor. When tested with a panel of human cancer cell lines, SKLB610 inhibited cell proliferation with IC50 value ranges from 2.2 μM to 25.6 μM. In HUVECs, SKLB610 showed inhibition on VEGF-stimulated cell proliferation as well as VEGFR2 phosphorylation, inhibited cell capillary tube formation in a dose-dependent manner [1]. The solubility of SKLB610 in water, Ethanol, Ethyl acetate, 0.5% Tween 80 and Nanosuspension is 0.34 μg/ml, 16500 μg/ml, 380μg/ml, 23μg/ml and 103μg/ml [2, 3].

In mouse model with HCT116 subcutaneous xenograft, administration of SKLB610 (12.5 mg/kg, 25 mg/kg and 50 mg/kg) for 10 days markedly delayed tumor growth in a concentration dependent manner. Further, after 30 days treatment SKLB610significantly suppressed tumor volume as 77.1 % at the dose of 50 mg/kg [1].

References:
[1].  Cao, Z.X., et al., SKLB610: a novel potential inhibitor of vascular endothelial growth factor receptor tyrosine kinases inhibits angiogenesis and tumor growth in vivo. Cell Physiol Biochem, 2011. 27(5): p. 565-74.
[2].  Luo, X., et al., Pharmacokinetic studies of a novel multikinase inhibitor for treating cancer by HPLC-UV. J Chromatogr Sci, 2013. 51(1): p. 17-20.
[3].  Huang, Y., et al., The preparation and evaluation of water-soluble SKLB610 nanosuspensions with improved bioavailability. AAPS PharmSciTech, 2013. 14(3): p. 1236-43.

Featured Products
New Products
 

References on SKLB610

The preparation and evaluation of water-soluble SKLB610 nanosuspensions with improved bioavailability.[Pubmed:23934433]

AAPS PharmSciTech. 2013 Sep;14(3):1236-43.

The aim of the study was to investigate the potential of nanosuspension to enhance the bioavailability of SKLB610 (Biopharmaceutical Classification System class II drug), a bioactive anticancer compound synthesized in our labs. SKLB610 nanosuspensions were prepared using wet media milling. Physicochemical characteristics of the nanosuspensions were evaluated, including particle size and distribution, dissolution, transmission electron microscopy, atomic force microscopy, thermogravimetric analysis, and X-ray powder diffractometry. The dissolution rate of SKLB610 was greatly improved in nanosuspensions, compared to crude SKLB610. Pharmacokinetic studies in rats demonstrated that the oral bioavailability of SKLB610 in nanosuspension (89.4%) was 2.6-fold higher than in coarse suspension (34.1%). Stabilizer type, milling time, and milling speed had a significant effect on particle size of the SKLB610 nanosuspensions. Nanosuspensions effectively improved the dissolution rate and bioavailability of the water-insoluble drug SKLB610 by reducing the compound particle size to the nanoscale and employing a proper formulation.

SKLB610: a novel potential inhibitor of vascular endothelial growth factor receptor tyrosine kinases inhibits angiogenesis and tumor growth in vivo.[Pubmed:21691074]

Cell Physiol Biochem. 2011;27(5):565-74.

Antagonizing angiogenesis-related receptor tyrosine kinase is a promising therapeutic strategy in oncology. In present study, we designed and synthesized a novel vascular endothelial growth factor receptor (VEGFR) inhibitor N-methyl-4-(4-(3-(trifluoromethyl) benzamido) phenoxy) picolinamide SKLB610 that potently suppresses human tumor angiogenesis. SKLB610 inhibited angiogenesis-related tyrosine kinase VEGFR2, fibroblast growth factor receptor 2 (FGFR2) and platelet-derived growth factor receptor (PDGFR) at rate of 97%, 65% and 55%, respectively, at concentration of 10muM in biochemical kinase assays. In vitro, SKLB610 showed more selective inhibition of VEGF-stimulated human umbilical vein endothelial cells (HUVECs) proliferation, and this proliferation inhibitory effect was associated with decreased phosphorylation of VEGFR2 and p42/44 mitogen-activated protein kinase (p42/44 MAPK). Antiangiogenic evaluation showed that SKLB610 inhibited the HUVECs capillary-tube formation on Matrigel in vitro and the sub-intestinal vein formation of zebrafish in vivo. Moreover, SKLB610 inhibited a panel of human cancer cells proliferation in a concentration-dependent manner and human non-small cell lung cancer cell line A549 and human colorectal cancer cell line HCT116 were most sensitive to SKLB610 treatment. In vivo, chronic intraperitoneally administration of SKLB610 at dose of 50mg/kg/d resulted in significant inhibition in the growth of established human A549 and HCT116 tumor xenografts in nude mice without exhibit toxicity. Histological analysis showed significant reductions in intratumoral microvessel density (CD31 staining) of 43-55% relative to controls depending on the specific tumor xenografts. In conclusion, the present study demonstrated that SKLB610 exhibited its antitumor activity as a multi-targeted inhibitor with more potent inhibition of VEGFR2 activity. Its potential to be a candidate of anticancer agent is worth being further investigated.

Description

SKLB610, a novel multi-targeted inhibitor, inhibits angiogenesis-related tyrosine kinase VEGFR2, FGFR2 and PDGFR at rate of 97%, 65% and 55%, respectively, at concentration of 10 μM in biochemical kinase assays.

Keywords:

SKLB610,1125780-41-7,Natural Products,VEGFR, buy SKLB610 , SKLB610 supplier , purchase SKLB610 , SKLB610 cost , SKLB610 manufacturer , order SKLB610 , high purity SKLB610

Online Inquiry for:

      Fill out the information below

      • Size:Qty: - +

      * Required Fields

                                      Result: